A Singular Vision
Relentless pursuit of transformative therapies targeting FcRn, a central mediator in autoimmune responses.
Rapid clinical advancement across multiple indications for our lead investigational candidate SYNT001.
FcRn plays a central role across a wide swath of autoimmune diseases affecting millions of people worldwide.
NEWS & PROGRESS
NOVEMBER 2, 2018
Alexion Completes Acquisition Of Syntimmune
@syntimmune | SEPTEMBER 21, 2018
Our scientists played pivotal roles in advancing understanding of the complex role of FcRn in IgG-mediated autoimmu… https://t.co/MsuJR9LzYf